The best overall outcomes were observed in anti-CFH antibody-mediated aHUS (no patients with CKD 3–5), whereas 23.4% (18/77) of patients with genetic and 26.1% (23/88) of no cause identified aHUS were in CKD 3–5 at last presentation. This evidence concerns the gene CFH and chronic kidney disease.